AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$LIVN

Bianchi Francesco sold $132K of LIVN

Bianchi Francesco sold 1,650 shares of LivaNova PLC (LIVN) at $79.72 ($0.13M total) on 2026-08-31.

Original reporting
SEC EDGAR · Bianchi Francesco
Published Sep 2, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LIVN
Neutral
high confidence
Mentioned
$LIVN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIVNNeutralLow
01

Why it matters

The disclosed sale is small and likely routine, offering limited trading insight.

02

Market read

Minor insider sale with low trading relevance.

03

What to watch

Potential upcoming board decisions or personal liquidity needs not disclosed.

Relevance 4/10Novelty 5/10Timing: filed today

Background

Form 4 filings disclose insider transactions; directors' sales are monitored for material signals.

Company-level read

Ticker impact

$LIVNNeutralHigh confidence
Context

Director Francesco Bianchi sold 1,650 shares for $131,538, reducing his stake to 7,934 shares.

Expected impact

Minimal short-term price pressure; unlikely to move the stock materially.

Evidence & confidence

The transaction size ($132K) is trivial for a mid-cap listed company, and no broader context suggests a larger trend.

Market effects

Sector

No significant impact on the medical device sector.

Regional

Limited effect on US markets; no regional ripple.

Global

Negligible.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Company
    LivaNova PLC

    Medical device manufacturer listed on NYSE (LIVN).

  • Insider
    Francesco Bianchi

    Director of LivaNova who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LIVN insider trading history →

Related articles

OCT 23
$LIVNMed

LivaNova PLC: Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

LivaNova PLC (LIVN) reported 36-month results from the CORE-VNS study, showing a 76% median reduction in seizure frequency for drug-resistant epilepsy patients using its VNS Therapy. The study also found improvements in quality of life, healthcare resource utilization, and seizure severity. The data was published in the journal Neuromodulation.

finanznachrichten.de3 min
OCT 23
$LIVNMedAI 8/10

A nerve-stimulation study found the share reporting seizure-related hospital stays fell 73% over three years.

LivaNova PLC (LIVN) reported that a 36-month study of its VNS Therapy for Drug-Resistant Epilepsy showed a 73% reduction in seizure-related hospitalizations, improved quality of life, and sustained benefits. The CORE-VNS study, published in Neuromodulation, involved 531 participants across 16 countries, with 426 completing follow-up. The company highlights the therapy's long-term effectiveness and safety.

stocktitan.net2 min
AUG 12
$LIVNMedAI 8/10

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.

fool.com6 min
AUG 7
$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

yahoo.com7 min